As a well-known domestic provider of R&D, manufacturing, integration and service for IVD reagents and instruments, Autobio committed to the promotion and advancement of medical laboratory technology, dedicated to serving human healthcare.
Autobio was listed on September 1, 2016 and is the first IVD company listed on the main board of the Shanghai Stock Exchange.In 2023, Autobio achieved operating income of 631 million dollars.